Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation

17Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

An innovative immunosuppressant with a minimally invasive delivery system has emerged in the biomedical field. The application of biodegradable and biocompatible polymer forms, such as hydrogels, scaffolds, microspheres, and nanoparticles, in transplant recipients to control the release of immunosuppressants can minimize the risk of developing unfavorable conditions. In this review, we summarized several studies that have used implantable immunosuppressant delivery to release therapeutic agents to prolong allograft survival. We also compared their applications, efficacy, efficiency, and safety/side effects with conventional therapeutic-agent administration. Finally, challenges and the future prospective were discussed. Collectively, this review will help relevant readers understand the different approaches to prevent transplant rejection in a new era of therapeutic agent delivery.

Cite

CITATION STYLE

APA

Anggelia, M. R., Huang, R. W., Cheng, H. Y., Lin, C. H., & Lin, C. H. (2022, February 1). Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms23031592

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free